PanTher Presents Phase 1 Trial-In-Progress Poster for Pancreatic Cancer Study at American Society of Clinical Oncology Gastrointestinal Cancers Symposium
PanTher Therapeutics presents “Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma – A Trial in Progress” poster at the American Society for Clinical Oncology 2023 Gastrointestinal Cancers Symposium (ASCO-GI), taking place in San Francisco, Calif., The poster highlights the trial-in-progress for the treatment of borderline resectable or locally advanced pancreatic ductal adenocarcinoma ongoing in Australia. PanTher Therapeutics’ CEO Laura Indolfi and study Principal Investigator John Zalcberg are present to answer any questions.
PanTher Therapeutics Billboard is Live in Times Square, New York, NY
PanTher Therapeutics’ mission of Attacking Cancer at the Source™ is shared from the famous Times Square billboards in New York City November 7-13, 2022. As part of a sponsored campaign with Brex, PanTher displays their mission to the mass of people visiting the major commercial intersection, tourist destination, and entertainment hub that is Times Square.
PanTher Reimagines Cardiology Interventions As Precision Oncology Platform (Requires login)
Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors. PanTher Therapeutics’ Sagitarri™ platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream leveraging interventional oncology procedures.
PanTher’s approach of “Attacking Cancer the Source” featured in the Nature Biopharma Dealmakers publication focused on the oncology landscape
PanTher Therapeutics is targeting solid tumors through direct, localized, and sustained delivery of therapeutic agents. The company’s lead program is in a phase 1 trial, and the company is seeking partners to further develop its platform. Leveraging decades of material science, pharmacology, and cancer biology, PanTher’s innovative approach is truly differentiated from current technologies. In a highly competitive innovative drug discovery market, PanTher’s technology focuses on optimizing the route of administration to unlock a drug’s full potential.
NEVY Awards Winner – “Emerging MedTech Company of the Year”
Last night the New England Venture Capital Association (NEVCA) honored the winners of its ninth annual NEVY Awards, recognizing and celebrating the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem — the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. We’re honored to receive the recognition for “Emerging MedTech Company of the Year” among Boston’s top startups and late-stage companies at the 9th annual NEVY Awards! 💥A big thank you to the New England Venture Capital Association and their Academy members for the recognition and a shoutout to our team 🦸🏻♀️🦹 that made this win possible.
Becoming A Clinical-Stage Biotech (Requires login)
Life Science Leader’s October 2019 issue featured Laura Indolfi, CEO and co-founder of PanTher Therapeutics, in an article titled “Program Winners Look Back On Year Of Change.” Her company, which makes minimally invasive implantable devices that deliver direct, localized, and sustained cancer therapy to solid tumors, won the first Massachusetts Next Generation Initiative (MassNext-Gen), a competitive program to support women entrepreneurs in early-stage life sciences companies. In June of 2021, PanTher closed an oversubscribed $5.4M Series A round, which set the stage for the company’s first clinical trial. Life Science Leader asked her to share some of her learnings from this key milestone and from the company’s decision to expand its board.